Late Breaking Abstracts

You can now submit Late Breaking Abstracts HERE as POSTERS ONLY. These abstracts will be posted only on the congress website, but they will be published in the European Journal of Clinical Pharmacology like the other abstracts. Abstract submitters must register for the virtual EACPT meeting.

Submission deadline 15 May.


New EACPT Virtual Meeting 2021 – Focus on Progress in Clinical Pharmacology

Abstract presenters (of abstracts submitted before the deadline 18 February) will be given the choice to either present abstracts virtually this year for the new EACPT Virtual Focus Meeting. 28-29 June 2021 OR save them for the postponed EACPT Congress in Athens, 26-28 June 2022 (see more details on the front page).

Please note that only abstracts that have NOT been previously published will be accepted. This means that abstracts can only be presented during the EACPT Congress next year in Athens if not published elsewhere in the meantime.

Acceptance guidelines

All abstracts received will be evaluated by a panel of experts. The submitting author will receive a confirmation of acceptance for oral presentation (only possible for abstracts submitted before the deadline 18 February), poster presentation, or a notice of rejection, by email by 30 April 2021. (Deadline for Late Breaking Abstract: End May)

• Language: Abstracts should be written in English.
• Abstract title: The title (including spaces) should not exceed 200 characters and should be written in sentence case. Please do not type a full stop (.) at the end of the title.
• Topics: When asked to select an abstract topic from the list provided, select at least one topic matching the content of your abstract best.
• Keywords: You may enter a maximum of 6 keywords, describing the content of your abstract for scheduling and indexing purposes. Avoid general terms.
• Abstract text: The abstract should not exceed 2.500 characters including spaces and punctuation. The abstract title is included in the overall character count. The abstract must be structured in the following five specified subtitles: Introduction, Objectives, Methods, Results and Conclusion. A table can be inserted for inclusion in the abstract.
• Registration of authors: Names, titles, institutional affiliations, cities, countries and email addresses of all contributing authors should be provided. The presenting author (not necessarily the first author) should be identified.
• Only abstracts not previously published will be accepted.

Abstract topics

Advanced therapies Immunotherapies
Antimicrobials Intensive care treatment
Bioinformatics and systems pharmacology Misuse of medicines/substances
Cancer treatment Nephropharmacology
Cardiovascular treatment Patient empowerment
Chronic diseases Pediatric treatment
Computerized decision support Pharmacogenetics/omics
COVID-19 therapies and vaccines Pharmacokinetics/pharmacodynamics
Drug regulation Pharmacovigilance
Drug utilization Professional development
Drug-drug interactions Psychopharmacology
Education Rare diseases
Geriatric treatment Therapeutic drug monitoring
Health economy